Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
5.06
-0.03 (-0.59%)
Aug 6, 2026, 12:10 PM EDT - Market open
Vanda Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 55.88 | 84.85 | 102.32 | 135.82 | 135.03 | 52.07 |
Short-Term Investments | 114.15 | 179 | 272.33 | 252.44 | 331.83 | 380.74 |
Cash & Short-Term Investments | 170.03 | 263.85 | 374.64 | 388.26 | 466.86 | 432.81 |
Cash Growth | -47.77% | -29.57% | -3.51% | -16.84% | 7.87% | 17.70% |
Accounts Receivable | 59.69 | 54.58 | 47.1 | 34.16 | 33.51 | 32.47 |
Inventory | 1.68 | 1.85 | 1.73 | 1.36 | 1.19 | 1.03 |
Other Current Assets | 33.09 | 26.99 | 15.42 | 9.17 | 17.73 | 12 |
Total Current Assets | 264.48 | 347.26 | 438.89 | 432.95 | 519.29 | 478.3 |
Net Property, Plant & Equipment | 23.95 | 13.51 | 12.68 | 9.14 | 10.97 | 12.39 |
Other Intangible Assets | 113.12 | 117.09 | 114.1 | 121.37 | 18.57 | 20.08 |
Other Long-Term Assets | 10.92 | 11.08 | 90.54 | 84.99 | 85.42 | 83.03 |
Total Assets | 412.47 | 488.95 | 656.2 | 648.44 | 634.25 | 593.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 69.99 | 68.3 | 39.09 | 38.46 | 45.55 | 34.44 |
Other Current Liabilities | 94.03 | 76.87 | 60.9 | 49.24 | 45.89 | 39.98 |
Total Current Liabilities | 164.03 | 145.16 | 99.98 | 87.7 | 91.44 | 74.42 |
Long-Term Leases | 18.2 | 7.07 | 8.09 | 7.01 | 8.81 | 10.06 |
Other Long-Term Liabilities | 10.05 | 9.53 | 9.59 | 8.83 | 6.8 | 4.39 |
Total Long-Term Liabilities | 28.26 | 16.6 | 17.68 | 15.83 | 15.61 | 14.45 |
Total Liabilities | 192.28 | 161.76 | 117.66 | 103.53 | 107.05 | 88.86 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-in Capital | 725.93 | 721.26 | 712.71 | 700.27 | 686.24 | 669.22 |
Accumulated Other Comprehensive Income | 0.04 | 0.63 | 0.07 | -0.03 | -1.19 | -0.18 |
Retained Earnings | -505.85 | -394.77 | -174.29 | -155.39 | -157.9 | -164.18 |
Shareholders' Equity | 220.19 | 327.19 | 538.55 | 544.91 | 527.2 | 504.93 |
Total Liabilities & Equity | 412.47 | 488.95 | 656.2 | 648.44 | 634.25 | 593.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 18.2 | 7.07 | 8.09 | 7.01 | 8.81 | 10.06 |
Net Cash (Debt) | 151.83 | 256.78 | 366.55 | 381.26 | 458.05 | 422.76 |
Net Cash Growth | -52.34% | -29.95% | -3.86% | -16.76% | 8.35% | 18.67% |
Net Cash Per Share | 2.55 | 4.36 | 6.30 | 6.62 | 8.04 | 7.43 |
Book Value | 220.19 | 327.19 | 538.55 | 544.91 | 527.2 | 504.93 |
Book Value Per Share | 3.70 | 5.55 | 9.26 | 9.47 | 9.25 | 8.87 |
Tangible Book Value | 107.07 | 210.1 | 424.45 | 423.54 | 508.63 | 484.85 |
Tangible Book Value Per Share | 1.80 | 3.57 | 7.30 | 7.36 | 8.93 | 8.52 |